Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma

Journal of Clinical Gastroenterology

Volumn 47, Issue 8, 2013, Pages 684-688

  Tabata, Chiharu ^a   Kanemura, Shingo ^a   Tabata, Rie ^a   Masachika, Eriko ^a   Shibata, Eisuke ^a   Otsuki, Tai Ichiro ^a   Nishizaki, Tomoyuki ^b   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

HMGB1; Mesothelioma; Tumor marker

Indexed keywords

ASBESTOS; HIGH MOBILITY GROUP B1 PROTEIN; MESOTHELIN;

ADULT; ARTICLE; ASBESTOSIS; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA; FEMALE; HUMAN; HUMAN TISSUE; MALE; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ASBESTOS; ASBESTOSIS; CASE-CONTROL STUDIES; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883232281     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318297fa65     Document Type: Article

References (36)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366: 397-408.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353: 1591-1603.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17: 260-271.
4. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;15: 2736-2740.
5. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18: 985-990.
6. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98: 268-272.
7. Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21: 348-353.
8. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103: 822-831.
9. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27: 6237-6242.
10. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362: 1612-1616.
11. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353: 1564-1573.
12. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer. 2009;100: 1175-1183.
13. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989; 243(4894 pt 1): 1056-1059.
14. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418: 191-195.
15. He M, Kubo H, Ishizawa K, et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1427-L1436.
16. Hamada N, Maeyama T, Kawaguchi T, et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39: 440-447.
17. Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72: 3290-3301.
18. Tabata C, Terada T, Tabata R, et al. Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol. 2013;47:e7-e11.
19. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5: 331-342.
20. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108: 949-955.
21. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosismediated sepsis lethality. J Exp Med. 2006;203: 1637-1642.
22. Takahashi K, Fukushima S, Yamahara K, et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation. 2008;118(suppl 14):S106-S114.
23. Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48: 971-981.
24. Rowe SM, Jackson PL, Liu G, et al. Potential role of highmobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med. 2008;178: 822-831.
25. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13: 2836-2848.
26. Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799: 131-140.
27. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGEamphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405: 354-360.
28. Poser I, Golob M, Buettner R, et al. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol. 2003;23: 2991-2998.
29. Völp K, Brezniceanu ML, Bösser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55: 234-242.
30. Brezniceanu ML, Völp K, Bösser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17: 1295-1297.
31. Liu PL, Tsai JR, Hwang JJ, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol. 2010;43: 530-538.
32. Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaBdependent pathway, a possible mechanism for asbestosinduced oncogenesis. Proc Natl Acad Sci USA. 2006;103: 10397-10402.
33. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227: 44-58.
34. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012;18: 598-604.
35. Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA. 2010;107: 12611-12616.
36. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30: 1541-1549.